October 6, 2014 / 12:07 PM / in 4 years

BUZZ-Tekmira Pharmaceuticals Corp: Brokerage downgrade

** Drugmaker’s U.S.-listed shares down 5 pct at $28 premarket

** Analysts at Leerink Partners downgrades to “market perform” from “outperform,” citing valuation and limited near-term visibility on stock-moving catalysts

** Analysts said significant profits from the company’s Ebola treatment, TKM-Ebola, is now “baked” into the stock

** Tekmira is one of the several companies developing treatments or vaccines for Ebola

** The stock has risen about 40 pct in the last one week on hopes that the Canadian company could win a U.S. contract for its Ebola treatment after the first case of the deadly infection was diagnosed in the United States

** Out of five analysts covering the stock, four have a “buy” or a higher rating and one has a “hold”, according to Thomson Reuters data

** Up to Friday’s close, the stock had risen 129 pct since May 27, a day after Sierra Leone first confirmed Ebola outbreak

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below